ArticleTechnological forecasting and social change2021
Effect evaluation of non-pharmaceutical interventions taken in China to contain the COVID-19 epidemic based on the susceptible-exposed-infected-recovered model.
Article in Technological forecasting and social change, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Data-driven strategies for model-informed decision-making during the COVID-19 pandemic: a systematic review.BMJ open · 2026Pooled it
- Epidemiological changes of scarlet fever before, during and after the COVID-19 pandemic in Chongqing, China: a 19-year surveillance and prediction study.BMC public health · 2024Article
- How can infectious medical waste be forecasted and transported during the COVID-19 pandemic? A hybrid two-stage method.Technological forecasting and social change · 2023Article
- Evaluating Effects of Dynamic Interventions to Control COVID-19 Pandemic: A Case Study of Guangdong, China.International journal of environmental research and public health · 2022Article
- The clinical and virological features of two children's coinfections with human adenovirus type 7 and human coronavirus-229E virus.Frontiers in public health · 2022Article
- Discretionary Effort on Green Technology Innovation: How Chinese Enterprises Act when Facing Financing Constraints.PloS one · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper takes confirmed cases of COVID-19 from January 20 to March 18, 2020 as the sample set to establish the susceptible-exposed-infected-recovered (SEIR) model. By evaluating effects of different non-pharmaceutical interventions (NPIs), the research expects to provide references to other countries for formulating corresponding policies. This article divides all non-pharmaceutical interventions into three types according to their different roles. The results show that type-A and type-B non-pharmaceutical interventions both can delay the timing of large-scale infections of the susceptible population, timing of the number of exposed individuals to peak, and timing of peaking of the number of infected cases, as well as decrease the peak number of exposed cases. Moreover, type-B non-pharmaceutical interventions have more significant effects on susceptible and exposed populations. Type-C non-pharmaceutical interventions for improving the recovery rate of patients are able to effectively reduce the peak number of patients, greatly decrease the slope of the curve for the number of infected cases, substantially improve the recovery rate, and lower the mortality rate; however, these non-pharmaceutical interventions do not greatly delay the timing of the number of infected cases to peak. And based on the above analysis, we proposed some suggestions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.